

## **PCL Department Publications (2010)**

### **Arnot M**

Arnot JA, **Arnot MI**, Mackay D, Couillard Y, MacDonald D, Bonnell M, Doyle P. Molecular size cut-off criteria for assessing bioaccumulation potential: fact or fiction? *Integr Environ Assess Manag.* 6(2): 210-224, 2010.

### **Brands B**

**Brands B**, Paglia-Boak A, Sproule BA, Leslie K, Adlaf EM. Nonmedical use of opioid analgesics among Ontario students. *Can Fam Physician.* Mar; 56(3):256-62, 2010.

Selby P, Voci SC, Zawertailo L, George T, **Brands B**. Individualized smoking cessation treatment in an outpatient setting: Predictors of outcome in a sample with psychiatric and addictions co-morbidity. *Addictive Behaviors.* 35(9):811-7, 2010

Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, **Brands B**. Clinical trial: The effect of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol – a randomized trial. *Alimentary Pharmacology and Therapeutics.* 32(3):478-86, 2010.

### **Burnham WM**

Higgins GA, Breyse N, Undzys E, Derksen DR, Jeffrey M, Scott BW, Xin T, Roucard C, Bressand K, Depaulis A, **Burnham WM**. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. *Psychopharmacology (Berl).* 207(4):513-27, 2010.

Taha AY, Jeffrey MA, Taha NM, **Burnham WM**. Acute administration of docosahexaenoic acid (DHA) increases resistance to pentylenetetrazol-induced seizures and elevates brain DHA in brain phospholipids in rats. *Epilepsy Behav.* 17(3):336-43, 2010.

Scott BW, Park Han , Wahidie A, **Burnham WM**. Extra-focal threshold reductions in amygdala-kindled rats. *Epilepsia.* e-pub Feb 26, 2010

Scott BW, Chan KF, Wong G, Ahmed M, Chievertson L, Liu RR., Wood J, **Burnham WM**. Cytogenesis in the adult rat dentate gyrus is increased following kindled seizures but is unaltered in pharmacological models of absence seizures. *Epilepsy Behav.* 18(3):179-85, 2010

Taha AY, **Burnham WM**, Auvin S. Polyunsaturated fatty acids and epilepsy. *Epilepsia.* 51(8):1348-58, 2010

### **Busto UE**

Kushnir V, Menon M, Balducci XL, Selby P, **Busto UE**, Zawertailo L. Enhanced smoking cue salience associated with depression severity in nicotine-dependent individuals: a preliminary fMRI study. *Int J Neuropsychopharmacol;* 7:1-12, 2010.

Busto A, Souza RP, Lobo DS, Shaikh SA, Zawertailo LA, **Busto UE**, Kennedy JL. Cocaine and amphetamine regulated transcript (CART) gene in the comorbidity of schizophrenia with alcohol use disorders and nicotine dependence. *Prog. Neuropsychopharmacol Biol Psychiatry*; 6;34(6):834-6, 2010.

Yasseen B, Kennedy JL, Zawertailo LA, **Busto UE**. Comorbidity between bipolar disorder and alcohol use disorder: association of dopamine and serotonin gene polymorphisms. *Psychiatry Res*; 30;176(1):30-3, 2010.

Zawertailo LA, Tyndale RF, **Busto UE**, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. *Hum Psychopharmacol*; 25(1):71-9, 2010.

Hussain S, Zawertailo L, **Busto UE**, Zack M, Farvolden P, Selby P. The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: a randomized controlled trial in unmotivated smokers. *Addict Behav.*; 35(2):164-7, 2010.

Zack M, Woodford TM, Tremblay AM, Steinberg L, Zawertailo LA, **Busto UE**. Stress and alcohol cues exert conjoint effects on Go and Stop signal responding in make problem drinkers. *Neuropsychopharmacology*; 36: 445-458, 2010.

### **Chirgadze N**

Robert Lam, Vladimir Romanov, Kathy Johns, Kevin Battaile, Jean Wu-Brown, Robert P. Hausinger, Emil Pai, and Nickolay Y. Chirgadze. Structure of the Helicobacter pylori Urease Accessory Protein UreF. *Proteins: Structure, Function, and Bioinformatics*. 78 (13): 2839-48. 2010.

Lorenzini E, Singer A, Singh B, Lam R, Skarina T, Chirgadze NY, Savchenko A, Gupta RS. Structure and protein-protein interaction studies on Chlamydia trachomatis protein CT670 (YscO Homolog). *J Bacteriol*. 192(11):2746-56. 2010.

### **Dorian P (23)**

Spertus J, **Dorian P**, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the atrial fibrillation effect on quality-of-life (AFEQT) questionnaire in patients with atrial fibrillation. *Circ Arrhythm Electrophysiol*, 15, 2010.

**Dorian P**, Hohnloser SH, Thorpe KE, Roberts RS, Kuck KH, Gent M, Connolly SJ. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). *Circulation*. 21;122(25):2645-52. 2010.

**Dorian P**. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. *J Cardiovasc Pharmacol Ther*. 15(4 Suppl):15S-8S. 2010.

Aves T, **Dorian P**. Paroxysmal atrial fibrillation and health-related quality of life: the importance of keeping score. *Europace*; 12(5):606-7, 2010.

Van Herendael H, **Dorian P**. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. *Vasc Health Risk Manag*; 9;6:465-72, 2010.

Andrade JG, Connolly SJ, **Dorian P**, Green M, Humphries KH, Klein GJ, Sheldon R, Talajic M, Kerr CR. Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). *Heart Rhythm*; 7(9):1171-7, 2010.

Talajic M, Khairy P, Levesque S, Connolly SJ, **Dorian P**, Dubuc M, Guerra PG, Hohnloser SH, Lee KL, Macle L, Nattel S, Pederson OD, Stevenson LW, Thibault B, Waldo AL, Wyse G, Roy D, on behalf of the AF-CHF Investigators. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. *J Am Coll Cardiol*; 55(17):1796-802, 2010.

Lane C, **Dorian P**, Ghosh N, Radina M, O'Donnell S, Thorpe K, Mangat I, Korley V, Pinter A. Limitations in the current screening practice of assessing left ventricular ejection fraction for a primary prophylactic implantable defibrillator in southern Ontario. *Can J Cardiol*. 26(3):e118-24. 2010.

Pinter A, **Dorian P**. New approaches to atrial fibrillation management: treat the patient, not the ECG. *Cardiovasc Ther*. 28(5):302-10, 2010.

Van Herendael H, Pinter A, Ahmad K, Korley V, Mangat I, **Dorian P**. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. *Europace*. 12(5):618-25. 2010.

**Dorian P**. Rate control in atrial fibrillation (Editorial). *N Engl J Med*; 362(15):1439-41, 2010.

Van Herendael H, Pinter A, Ahmad K, Korley V, Mangat I, **Dorian P**. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. *Europace*. 12(5): 618-25, 2010.

Le Heuzey JY, Breithardt G, Camm J, Crijns H, **Dorian P**, Kowey P, Merioua I, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub W. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. *Am J Cardiol*; 105(5):687-93, 2010.

Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, **Dorian P**, Simpson CS, Khaykin Y, Cameron D, Janmohamed A, Yee R, Austin PC, Chen Z, Hardy J, Tu JV; Investigators of the Ontario ICD Database. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. *J Am Coll Cardiol*. 23;55(8):774-82. 2010.

Ramadeen A, Laurent G, dos Santos CC, Hu X, Connelly KA, Holub BJ, Mangat I, **Dorian P**. n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. *Heart Rhythm*. 7(4):520-8. Epub 2009, 2010.

Brooks SC, Schmicker RH, Rea TD, Aufderheide TP, Davis DP, Morrison LJ, Sahni R, Sears GK, Griffiths DE, Sopko G, Emerson SS, **Dorian P**; ROC Investigators. Out-of-hospital cardiac

arrest frequency and survival: evidence for temporal variability. *Resuscitation*. 81(2):175-81, 2010

### **Endrenyi L**

**Endrenyi L** and Schall R. Bioequivalence: tried and tested. *Cardiovasc. J. Africa*, 21: 69-70. 2010.

Schall R, **Endrenyi L** and Ring A. Residuals and outliers in replicate design crossover studies. *J. Giopharm. Stat.* 20: 835-849. 2010.

**Endrenyi L** and tothfalusi L. Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products? *J. Pharm. Pharmaceut. Sci.* 13: 107-113. 2010.

### **Finkelstein Y**

Schechter T, McCarhty C, **Finkelstein Y**, Doyle J, Lee L. Dupuis. Dismal Response to High-Dose Methylprednisolone after Failure to Respond to Standard Dose in Patients with Acute GVHD. *Bone Marrow Transplantation* 8, 2010. [ePub ahead of print]

Nurmohamed L, Garcia-Bournissen F, Buono R, Shannon MW, **Finkelstein Y**. Predisposition to Epilepsy-Does the ABCB1 Gene Play a Role? *Epilepsia* 51(9):1882-85(4), 2010.

Nussinovitch U, **Finkelstein Y**, Harel D, Nussinovitch N, Nussinovitch M. Pattern of Cerebrospinal Fluid Lactic Dehydrogenase During Treatment of Bacterial Meningitis. *Pediatr Neurol* 42(6):413-6, 2010

Pollock-BarZiv SM, **Finkelstein Y**, Manlhiot C, Dipchand AI, Hebert D, Ng VL, Solomon M, McCrindle BW, Grant D. Variability in Tacrolimus Blood Levels Increases the Risk of Late Rejection and Graft Loss after Solid Organ Transplantation in Older Children. *Pediatric Transplantation*;14(8):968-75, 2010.

Freedman S, Powell E, Nava-Ocampo AA, **Finkelstein Y**. Ondansetron in Pediatric Gastroenteritis: A Prospective Cohort, Dose-Response Study. *Pediatric Drugs* 12(6): 405-10, 2010.

**Finkelstein Y**, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. *Clin Toxicol* 48(5):407-14, 2010. (Invited Review by Editor)

Dubnov-Raz G, Koren G, **Finkelstein Y**. Selective serotonin reuptake inhibitor exposure in pregnancy and neonatal adverse events. *Arch Pediatr Adolesc Med* Apr;164(4):394, 2010.

**Finkelstein Y**, Schechter T, Freedman SB. Surgical masks vs N95 respirators for preventing influenza. *JAMA* 10:303(10):938, 2010.

## **George SR**

Ng J, Rashid AJ, So CH, O'Dowd BF, **George SR**. Activation of calcium/calmodulin-dependent protein kinase IIalpha in the striatum by the heteromeric D1-D2 dopamine receptor complex. *Neuroscience*; 165: 535-541, 2010.

Hasbi A, O'Dowd BF, **George SR**. Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. *Current Opinion in Pharmacology*; 10:93-99, 2010.

El-Ghundi M, Fan T, Karasinska J, Yeung J, Zhou M, O'Dowd BF and **George SR**. Restoration of amphetamine induced locomotor sensitization in dopamine D1 receptor deficient mice. *Psychopharmacology*; 207: 599-618, 2010.

Kabli N, Martin N, Hasbi A, Fan T, Nguyen T, Balboni GF, O'Dowd BF, **George SR**. Agonists at the delta opioid receptor modify the binding of mu receptor agonists to the mu-delta receptor heterooligomer. *British J Pharmacology*: 161: 1122-1136, 2010.

Perreault ML, Hasbi A, Alijaniam M, Fan T, Varghese G, Fletcher PJ, Seeman P, O'Dowd BF, **George SR**. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: Increased high affinity state following amphetamine and in schizophrenia. *J Biological Chemistry*; 285: 36625-36634, 2010.

Verma V, Hasbi A, O'Dowd BF, **George SR**. D1-D2 receptor heteromer mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: A dual functional role for GRK2. *J Biological Chemistry*; 285: 35092-35103, 2010.

Sawka AM, Straus S, Gafni A, Meiyappan S, O'Brien MA, Brierley JD, Tsang RW, Rotstein L, Thabane L, Rodin G, **George SR**, Goldstein DP. A usability study of a computerized decision aid to help patients with early stage papillary thyroid carcinoma in decision making on adjuvant radioactive iodine treatment. *Patient Education and Counseling*, epub Aug 21, 2010.

Lee DK, Ferguson SSG, **George SR**, and O'Dowd BF. The fate of the internalized apelin receptor is determined by different isoforms of apelin mediating differential interaction with beta-arrestin. *Biochemical Biophysical Research Communication*; 395: 185-189, 2010.

Khelashvili G, Dorff K, Shan J, Camacho-Artacho M, Skrabanek L, Vroiling B, Bouvier M, Devi L, **George SR**, Javitch JA, Lohse MJ, Milligan G, Neubig RR, Palczewski K, Parmentier M, Pin J-P, Vriend G, Campagne F, Filizola M. GPCR-OKB: The G protein coupled receptor-oligomer knowledge base. *Bioinformatics*; 26: 1804-1805, 2010.

Perreault M, Verma V, O'Dowd BF and **George SR**. Regulation of dopamine receptor responsiveness. In: *Dopamine Receptors*, Eds. K. Neve, Humana Press, 193-218, 2010.

Hasbi A, O'Dowd BF, **George SR**. Signaling of dopamine receptor homo- and heterooligomers. In: *G protein-coupled receptors: Structure, Signaling and Physiology*, Cambridge University Press, 2010.

## **Haas DA**

**Haas DA** Preparing dental office staff members for emergencies. Developing a basic action plan. *Journal of the American Dental Association*, 141:8S-13S, May 2010.

Garisto GA, Gaffen AS, Lawrence HP, Tenenbaum HC, **Haas DA**. Paresthesia Incidence Following Dental Local Anesthetic Administration in the United States. *Journal of the American Dental Association*, 141(7): 836-847, 2010.

Barcelos KC, Furtado DP, Ramacciato JC, Cabral AM, **Haas DA**. Effect of pCO<sub>2</sub> and pO<sub>2</sub> on lidocaine and articaine toxicity. *Anesthesia Progress*, 57:104-108, 2010.

Moore PA, **Haas DA**. Paresthesias in Dentistry. *Dental Clinics of North America*, 54:705-710, 2010.

**Haas DA**. "Drugs in Dentistry". In, *Compendium of Pharmaceuticals and Specialties (CPS)*, pages L20-L23, 2010.

## **Hampson D**

Jordan E. Antflick, Glen B. Baker, and **David R. Hampson**. The Effects of a Low Protein Diet on Amino Acids and Enzymes in the Serine Synthesis Pathway. *Amino Acids* 39, 145-153, 2010.

Arthur D. Conigrave and **David R. Hampson**. Broad-spectrum amino acid-sensing class C G-protein coupled receptors: molecular mechanisms, physiological significance and options for drug development. *Pharmacology and Therapeutics*, 127, 252-260, 2010.

J. Ellegood, L.K. Pacey, **D.R. Hampson**, J.P. Lerch, R.M. Henkelman. Alterations in the Cerebellum of a Mouse Model of Fragile X Syndrome Identified using Magnetic Resonance Imaging and Computed Tomography. *NeuroImage* 53, 1023-1029, 2010.

Daniel C. Adusei, Laura K.K. Pacey, Duke Chen, and **David R. Hampson**. Early Developmental Alterations in GABAergic Protein Expression in Fragile X Knockout Mice, *Neuropharmacology* 59, 167-171, 2010.

Gail R. Rauw, Suzanne L. Grant, Viviane Labrie, John Roder, Jordan Antflick, **David R. Hampson** and Glen B. Baker. Determination of L-serine-O-phosphate (L-SOP) in brain tissue using high performance liquid chromatography (HPLC) and fluorimetric detection. *Analytical Biochemistry* 405(2), 260-02, 2010.

## **Heersche JN**

Gramoun A, Azizi N, Sodek J, **Heersche JN**, Nakchbandi I, Manolson MF. Fibronectin inhibits osteoclastogenesis while enhancing osteoclast activity via nitric oxide and interleukin-1 $\beta$ -mediated signaling pathways. *J Cell Biochem.* 1;111(4):1020-34, 2010.

Gramoun A, Goto T, Nordström T, Rotstein OD, Grinstein S, **Heersche JN**, Manolson MF. Bone matrix proteins and extracellular acidification: potential co-regulators of osteoclast morphology. *J Cell Biochem.* 1; 111(2):350-61, 2010.

Trebec-Reynolds DP, Voronov I, **Heersche JN**, Manolson MF. VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha. *J Cell Biochem.* 15;110(2):343-51, 2010.

Trebec-Reynolds DP, Voronov I, **Heersche JN**, Manolson MF. IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts. *J Cell Biochem.* 1; 109(5):975-82, 2010.

### **Higgins G**

**Higgins GA**, Breyse N, Undzys E, Derksen R, Jeffrey M, Scott BW, Xin T, Rouchard C, Bressand K, Depaulis A, Burnham WM. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. *Psychopharmacology* 207: 513-527. 2010.

Fletcher PJ, Sinyard J, **Higgins GA**. Genetic and pharmacological evidence that 5-HT<sub>2C</sub> receptor activation, but not inhibition, affects motivation to feed under a progressive schedule of reinforcement. *Pharmacol. Biochem. Behav.* 97: 170-178. 2010.

### **Inaba T**

Trottier J, Hussein D, Perreault M, Pâquet S, Caron P, Bourassa S, Verreault M, **Inaba T**, Poirier GG, Bélanger A, Guill emette C, Taauner M and Barbier O. The human UGT 1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver. *J Biol Chem.* 8:285(2): 1113-21, 2010.

Trottier J, Verreault M, Grepper S, Monté D, Bélanger J, Kaeding J, Caron P, **Inaba T**, T Barbier O. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates cheno-deoxycholic acid in the liver. *Hepatology*,; 44(5): 1158-70, 2010.

### **Ito S**

Garcia-Bournissen F, Altchek J, Paunchaud A, **Ito S**. Is nifurtimox for treatment for Chagas disease compatible with breastfeeding? *Arch Dis Child*; 95:224-228. 2010.

Tanaka T, **Ito S**. Novel H1N1 influenza and pregnancy. *Expert Opinion in Obstetrics and Gynecology*; 5:169-175. 2010

Chuang A, **Ito S**. Ambient tonicity and intestinal CYP3A. *Expert Opinion in Drug Metabolism*,; 6:883-893. 2010.

**Ito S**, Carleton B. Predictive genotype. *CMAJ* 182(8):804. 2010.

Tan KP, Wood GA, Yang M, **Ito S**. Participation of Nuclear Factor (Erythroid 2-Related) Factor 2 (Nrf2) in ameliorating lithocholic acid-induced cholestatic liver injury in mice. *Br J Pharmacol*; 161:1111-1121. 2010.

Tan KP, Wang B, Yang M, Boutros PC, MacAulay J, Xu H, Chuang AI, Kosuge K, Yamamoto M, Takahashi S, Wu A, Ross DD, Harper PA, **Ito S**. Aryl hydrocarbon receptor (AHR) is a transcriptional activator of human breast cancer resistance protein (BCRP/ABCG2). *Mol Pharmacol*; 78:175-185. 2010.

### **Kalant J**

**H. Kalant** Obituary: H. David Archibald (22 July 1919 – 12 July 2009). *Addiction* 105: 566-567, 2010.

**H. Kalant** What neurobiology cannot tell us about addiction. *Addiction* 105: 780-789, 2010.

**H. Kalant** Response to commentaries on “What neurobiology cannot tell us about addiction”. *Addiction* 105: 795-796, 2010.

**H. Kalant** Drug Classification – Science, Politics, Both or Neither? *Addiction* 105: 1146-1149, 2010.

**H. Kalant** Reply to the commentaries. *Addiction* 105: 1154-1155, 2010.

### **Kish SJ**

Callaghan RC, Cunningham JK, Sajeev G, **Kish SJ**. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. *Mov Disord*. 30;25(14):2333-9. 2010.

**Kish SJ**, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[<sup>11</sup>C]DASB and structural brain imaging study. *Brain*. 133(Pt 6):1779-97, 2010.

Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J, Selby P, Wilson AA, **Kish SJ**. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[<sup>11</sup>C]DTBZ study in humans. *Synapse*. 64(6):417-20, 2010.

Boileau I, Guttman M, Rusjan P, Adams JR, House S, Tong J, Hornykiewicz O, Wilson AS, Kapur S, **Kish SJ**. Decreased binding of the D3 dopamine receptor-preferring ligand [<sup>11</sup>C]-(+)-PHNO in drug-naïve Parkinson's disease. *Brain* 132: 1365-75, 2010.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muentner MD, **Kish SJ**, Hornykiewicz O, Furukawa Y. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: A comparative investigation. *Bain* 133: 172-88, 2010.



**Kish SJ**, Fitzmaurice PS, Chang L-J, Furukawa U, Tong J. Low striatal serotonin transporter protein in a human ploydrug mdma (estasy) user: A case study. *J. Psychopharmacology* 24 281-4, 2010.

**Koren G** (71)

Matok I, Gorodischer R, **Koren G**. Sheiner E, Wiznitzer A, Uziel E, Levy A: The safety of h2-blockers use during pregnancy. *J Clin Pharmacol.* 50: 81-7, 2010.

Banach R, Boskovic R, Einarson T, **Koren G**. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. *Drug Saf.* 33: 73-9, 2010.

Moller M, Aleksa K, Walasek P, Karaskov T, **Koren G**. Solid-phase microextraction for the detection of codeine, morphine and 6-monoacetylmorphine in human hair by gas chromatography-mass spectrometry. *Forensic Sci Int.* Jan 16, 2010.

Gunness P, Aleksa K, **Koren G**. The effect of acyclovir on the tubular secretion of creatinine in vitro. *J Transl Med.* 8: 139, 2010.

Kennedy DA, Stern SJ, Matok I, Sarkar M, Nickel C, **Koren G**. Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. *Cancer Epidemiol.* Dec. 20, 2010.

Elzagallaai AA, Jahedmotlagh Z, Del Pozzo-Magana BR, Knowles SR, Prasad AN, Shear NH, Rieder MJ, **Koren G**. Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndrome. *Mol Diagn Ther.* 14: 317-22, 2010.

**Koren G**, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, Mattison DR. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. *Am J Obstet Gynecol.* 203: 1-7, 2010.

Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, **Koren G**. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. *Pediatrics.* 126: 986-9, 2010.

Madadi P, Joly Y, Avarad D, Chitayat DC, Smith MA, Ross CJ, Carleton BC, Hayden MR, **Koren G**. Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits. *Clin Pharmacol Ther.* 88: 792-5, 2010.

Goh YI, Hutson JR, Lum L, Roukema H, Gareri J, Lynn H, **Koren G**. Rates of fetal alcohol exposure among newborns in a high-risk obstetric unit. *Alcohol.* 44: 629-34, 2010.

Grupp SG, Greenberg ML, Ray JG, Busto U, Lanctot KL, Nulman I, **Koren G**. Pediatric cancer rates after universal folic acid flour fortification in Ontario. *J Clin Pharmacol.* 51: 60-5, 2011.

Elzagallaai AA, Rieder MJ, **Koren G**. The in vitro platelet toxicity assay (iPTA): A novel approach for assessment of drug hypersensitivity syndrome. *J Clin Pharmacol.* April 16, 2010.

Hutson JR, **Koren G**, Matthews SG. Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. *Placenta*. 31: 351-7, 2010.

Pollex EK, Feig DS, Lubetsky A, Yip PM, **Koren G**. Insulin glargine safety in pregnancy: a transplacental transfer study. *Diabetes Care*. 33: 29-33, 2010.

Moller M, **Koren G**. Unsuspected prenatal opioid exposure: long-term detection by alternative matrices. *Ther Drug Monit*. 32: 1-2, 2010.

### **Lança AJ**

**Lança AJ**. Hyperlipidemias and Cardiovascular Disease. CME Resource, Sacramento CA, USA: ([http://www.netce.com/659/Course\\_9084.pdf](http://www.netce.com/659/Course_9084.pdf)) 2010.

**Lança AJ**. Herbal Medications: An Evidence-Based Review. 2<sup>nd</sup> edition. CME Resource, Sacramento CA, USA: ([http://www.netce.com/645/Course\\_9839.pdf](http://www.netce.com/645/Course_9839.pdf)) 2010.

### **Lanctôt KL (19)**

Dowlati Y, Herrmann N, Swardfager W, Reim EK, **Lanctôt KL**. Efficacy and safety of antidepressants for the treatment of depression in coronary artery disease: a meta-analysis. *Can J Psychiatry*; 55(2):91-99, 2010.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, **Lanctôt KL**. A meta-analysis of cytokines in major depression. *Biol Psychiatry*; 67(5):446-457, 2010.

**Lanctôt KL**, Rapoport MJ, Chan F, Rajaram R, Strauss J, Sicard T, McCullagh S, Feinstein A, Kiss A, Kennedy JL, Bassett AS, Herrmann N. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. *Brain Injury*; 24(7-8):959-69, 2010.

Swardfager WL, Herrmann N, Marzolini S, Saleem M, Kiss A, Shammi P, Oh PI, **Lanctôt KL**. Cardiopulmonary fitness is associated with cognitive performance in patients with coronary artery disease. *JAGS*; 58(8):1519, 2010.

Smart KA, Paes BA, **Lanctôt KL**. The cost-effectiveness of palivizumab: a systematic review of the evidence. *J Med Econ*; 13(3):453-63, 2010.

Dowlati Y, Herrmann N, Swardfager W, Thomson S, Oh P, Van Uum S, Koren G, **Lanctôt KL**. Relationship between hair cortisol concentrations and depressive symptoms in patients with coronary artery disease. *Neuropsychiatr Dis Treat*; 7; 6:393-400, 2010.

Rothenburg LS, Herrmann N, Swardfager WL, Black SE, Tennen G, Gladstone DJ, Ween J, Snaiderman A, **Lanctôt KL**. The relationship between inflammatory markers and post-stroke cognitive impairment. *J Geriatr Psychiatry Neurol*.; 23(3):199-205, 2010.

Cappell J, Herrmann N, Cornish SA, **Lanctôt KL**. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. *CNS Drugs*, 1;24(11):909-27, 2010.

Swardfager W, **Lanctôt K**, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. *Biological Psychiatry*; 15;68(10):930-41, 2010.

Smart K, Paes B, **Lanctôt KL**. Changing costs and the impact on RSV prophylaxis; 13(4):705-8, 2010.

Herrmann N, Tam DK, Balshaw R, Sambrook R, Lesnikova N, **Lanctôt KL** and the COSID Investigators. The relationship between disease severity and cost of caring for patients with Alzheimer's disease in Canada. *Can J Psychiatry*; 55(12):768-75, 2010.

Gold A, Herrmann N, **Lanctôt KL**. Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-stroke sequelae. *Current Drug Targets*; 12(2):243-55, 2010.

Herrmann N, Black SE, Li A, **Lanctôt KL**. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. *International Psychogeriatrics*; 23(4):539-45, 2010.

Mitchell R, Herrmann N, **Lanctôt KL**. The role of dopamine in symptoms and treatment of apathy in Alzheimer's Disease. *CNS Neurosci Therapeutics*; 16, 2010.

Swardfager WL, Herrmann N, Marzolini S, Saleem M, Farber S, Kiss A, Oh PI, **Lanctôt KL**. Major depressive disorder predicts completion, adherence and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. *J Clin Psychiatry e-pub* 2, 2010.

### **Le AD**

**Lê AD**, Lo S., Harding S, Juzytsch W, Marinelli P and Funk D . Coadministration of intravenous nicotine and oral alcohol in rats. *Psychopharmacology* 208:475-486, 2010

Vecchio LM, Grace KP, Liu H, Harding S, **Lê AD**, Horner RL. State dependent versus Central effects of ethanol on Breathing . *J Appl Physiol* , 108: 287-300. 2010.

Shram MJ, **Lê AD**. Adolescent male Wistar rats are more responsive than adult rats to the conditioned rewarding effects of intravenously administered nicotine in the place conditioning procedure. *Behav Brain Res*. 206:240-244. 2010.

Marinelli PW, Funk D, Juzytsch W, **Lê AD**. Opioid receptors in the basolateral amygdala but not dorsal hippocampus mediate context-induced alcohol seeking. *Behav. Brain Research* 211:58-63. 2010.

Kupferschmidt DA, Funk D, Erb S, **Lê AD**. Age related effects of nicotine on behavioral and neurochemical measure of anxiety. *Behav Brain Res*. 2010 ,213(2):288-92. 2010.

## **Le Foll B**

Novak G, Seeman P, **Le Foll B**. Exposure to nicotine produces an increase in dopamine D2(High) receptors: a possible mechanism for dopamine hypersensitivity. *Int J Neurosci*. 120(11):691-7. 2010.

Souza RP, Meltzer HY, Lieberman JA, **Le Foll B**, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. *Hum Psychopharmacol*. ;25(7-8):582-5. 2010  
Li SX, Liu LJ, Jiang WG, Sun LL, Zhou SJ, **Le Foll B**, Zhang XY, Kosten TR, Lu L. Circadian alteration in neurobiology during protracted opiate withdrawal in rats. *J Neurochem*. 115(2):353-62. 2010.

Zai CC, Manchia M, De Luca V, Tiwari AK, Squassina A, Zai GC, Strauss J, Shaikh SA, Freeman N, Meltzer HY, Lieberman J, **Le Foll B**, Kennedy JL. Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. *Prog Neuropsychopharmacol Biol Psychiatry*. 1;34(8):1412-8. 2010.

Novak G, Zai CC, Mirkhani M, Shaikh S, Vincent JB, Meltzer H, Lieberman JA, Strauss J, Lévesque D, Kennedy JL, **Le Foll B**. Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder. *Genes Brain Behav*. 9(8):910-7, 2010.

Novak G, LeBlanc M, Zai C, Shaikh S, Renou J, DeLuca V, Bulgin N, Kennedy JL, **Le Foll B**. Association of polymorphisms in the BDNF, DRD1 and DRD3 genes with tobacco smoking in schizophrenia. *Ann Hum Genet*. 74(4):291-8. 2010.

Forget B, Wertheim C, Mascia P, Pushparaj A, Goldberg SR, **Le Foll B**. Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. *Neuropsychopharmacology*. 35(8):1751-60. 2010.

Forget B, Pushparaj A, **Le Foll B**. Granular insular cortex inactivation as a novel therapeutic strategy for nicotine addiction. *Biol Psychiatry*. 1;68(3):265-71. 2010.

Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, **Le Foll B**. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. *Psychiatr Genet*. 20(1):39-43, 2010.

Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaál J, **Le Foll B**. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. *Int. J Neuropsychopharmacol*. 13(2):181-90. 2010.

## **Li PP**

Perova T, Kwan M, **Li PP**, Warsh JJ. Differential modulation of intracellular Ca<sup>2+</sup> responses in B lymphoblasts by mood stabilizers. *Int J Neuropsychopharmacol*. 13:693-702, 2010.

## **Matthews J**

Macpherson L, **Matthews J**. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor  $\alpha$  expression in human breast cancer cells. *Cancer Lett.* 28; 299(2):119-29. 2010.

Celius T, **Matthews J**. Functional analysis of six human aryl hydrocarbon receptor variants in human breast cancer and mouse hepatoma cell lines. *Toxicology.* 9; 277(1-3):59-65, 2010.

Celius T, Pansoy A, **Matthews J**, Okey AB, Henderson MC, Krueger SK, Williams DE. Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver. *Toxicol Appl Pharmacol.* 15; 247(1):60-9. 2010.

Lo R, **Matthews J**. A new class of estrogen receptor beta-selective activators. *Mol Interv.;* 10(3):133-6, 2010.

Pansoy A, Ahmed S, Valen E, Sandelin A, **Matthews J**. 3-methylcholanthrene induces differential recruitment of aryl hydrocarbon receptor to human promoters. *Toxicol Sci.;* 117(1):90-100, 2010.

Lo R, Burgoon L, Macpherson L, Ahmed S, **Matthews J**. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. *Biochim Biophys Acta.;* 1799(5-6):469-79, 2010.

## **McIntyre RS (22)**

Soczynska JK, Kennedy SH, Woldeyohannes HO, Liauw SS, Alsuwaidan M, Yim CY, **McIntyre RS**. Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus. *Neuromolecular Med.* 2010.

Jerrell JM, **McIntyre RS**. Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study. *Prim Care Companion J Clin Psychiatry;* 12(4), 2010.

Kucyi A, Alsuwaidan MT, Liauw SS, **McIntyre RS**. Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. *Postgrad Med.;* 122(6):107-16, 2010.

Lipsman N, **McIntyre RS**, Giacobbe P, Torres C, Kennedy SH, Lozano AM. Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. *Bipolar Disord.;* 12(7):691-701, 2010.

**McIntyre RS**, Kennedy SH, Soczynska JK, Nguyen HT, Bilkey TS, Woldeyohannes HO, Nathanson JA, Joshi S, Cheng JS, Benson KM, Muzina DJ. Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. *Prim Care Companion J Clin Psychiatry;* 12(3), 2010.

Jerrell JM, **McIntyre RS**, Tripathi A. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. *Clin Schizophr Relat Psychoses*; 4(3):161-8, 2010.

**McIntyre RS**, Woldeyohannes HO, Soczynska JK, Miranda A, Lachowski A, Liauw SS, Grossman T, Lourenco MT, Kim B, Alsuwaidan MT, Kennedy SH. The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. *Adv Ther.*; 27(11):828-36, 2010.

**McIntyre RS**, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, Lo AK, Soczynska JK, Woldeyohannes H, Alsuwaidan M, Yoon J, Kennedy SH. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. *CNS Drugs*. 1;24(9):741-53, 2010.

Liauw SS, **McIntyre RS**. Atypical antipsychotic tolerability and switching strategies in bipolar disorder. *Expert Opin Pharmacother*;11(17):2827-37,2010.

**McIntyre RS**, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. *J Eval Clin Pract.*; 16(4):744-5, 2010.

**McIntyre RS**, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, Kucyi A, Soczynska JK, Woldeyohannes HO, Lachowski A, Kim B, Nathanson J, Alsuwaidan M, Taylor VH. Bipolar disorder and metabolic syndrome: an international perspective. *J Affect Disord.*; 126(3):366-87, 2010.

**McIntyre RS**, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. *J Affect Disord.*; 126(3):358-65, 2010.

**McIntyre RS**. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. *Expert Rev Neurother.* ;10(5):645-9, 2010.

**McIntyre RS**, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO, Adams AK, Cheng JS, Lourenco M, Kennedy SH, Rasgon NL. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? *Adv Ther.*; 27(2):63-80, 2010.

**McIntyre RS**, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *J Affect Disord.*; 122(1-2):27-38, 2010.

### **Meyer JH**

Sacher J, Wilson AA, Houle S, Hassan S, Rusjan P, Bloomfield P, Stewart D, **Meyer JH**. Elevated Brain Monoamine Oxidase A Binding In Human Early Postpartum. *Arch Gen Psych*; 67(5):468-74, 2010.

## **Milgram NW**

Pop V, Head E, Hill MA, Gillen D, Berchtold NC, Muggenburg BA, **Milgram NW**, Murphy MP, Cotman CW. Synergistic effects of long-term antioxidant diet and behavioral enrichment on beta-amyloid load and non-amyloidogenic processing in aged canines. *J Neurosci.* 21;30(29):9831-9, 2010.

Pan Y, Larson B, Araujo JA, Lau W, de Rivera C, Santana R, Gore A, **Milgram NW**. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. *Br J Nutr.*; 103(12):1746-54, 2010.

Trepanier CH, **Milgram NW**. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? *J Alzheimers Dis.*; 21(4):1089-99, 2010.

Collison KS, Makhoul NJ, Inglis A, Al-Johi M, Zaidi MZ, Maqbool Z, Saleh SM, Bakheet R, Mondreal R, Al-Rabiah R, Shoukri M, **Milgram NW**, Al-Mohanna FA. Dietary trans-fat combined with monosodium glutamate induces dyslipidemia and impairs spatial memory. *Physiol Behav.* 3;99(3):334-42, 2010.

Creed MC, and **Milgram NW**. Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. *Age (Dordr).*; 32(3):365-84, 2010.

Araujo JA, de Rivera C, Ethier JL, Landsberg GM, Denenberg S, Arnold S, and **Milgram NW**. ANXITANE® tablets reduce fear of human beings in a laboratory model of anxiety-related behavior. *Journal of Veterinary Behavior*, 5(5): 268-275, 2010.

## **Mitchell J**

**Mitchell J**, Lai LP, Peralta F, Xu Y, Sugamori K.  $\beta_2$ -Adrenergic Receptors Inhibit the Expression of Collagen Type II in Growth Plate Chondrocytes by Stimulating the AP-1 Factor Jun-B. *Am J Physiol Endocrinol Metab.* 2010 Dec 21 (Epub ahead of print).

**Mitchell J**, Swardfager W. The photoresponse in squid. In: *Encyclopedia of the Eye*, Four-Volume Set. Edited by J. Besharse et al., Elsevier, 3: 347-353, 2010.

## **Mittmann N**

Jang RW, Isogai P, **Mittmann N**, Bradbury P, Shepherd FA, Feld R, Leighl N . Derivation of utility values from EORTC QLQ-C30 values in lung cancer. *Journal of Thoracic Oncology*; 5(12): 1953-1957, 2010.

**Mittmann N**, Evans WK, Rocchi A, Longo CJ, Au H-J, Husereau D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Guidelines for health technologies: specific guidance for oncology products. *Value in Health* (submitted December 2010).

Lathia N, Isogai P, Cheung MC, **Mittmann N**. Study inclusion and presentation in a meta-analysis of G-CSF for prevention of febrile neutropenia. *Journal of Clinical Oncology*; 28(36): e762-e763, 2010.

Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, Rourke S, Rueda S, Rachlis A, **Mittmann N**, Smieja M, Collins E, Loutfy MR. Once daily dosing improves adherence to antiretroviral therapy. *AIDS & Behavior* 2010 Sep 28 [Epub ahead of print].

Bradbury P, Seymour L, Tu D, Isogai P, Zhu L, Ng R, **Mittmann N**, Tsao M, Evans W, Shepherd F, Leigh N. An economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. *Journal of the National Cancer Institute*; 102(5): 298-306, 2010.

Lathia N, **Mittmann N**, DeAngelis C, Knowles S, Cheung M, Piliotis E, Shear N, Walker S. Evaluation of direct medical costs of hospitalization for febrile neutropenia. *Cancer*; 116(3): 742-8, 2010.

**Mittmann N**, Trudeau M, Alloul K, Koo M, Verma S. Cost effectiveness of TAC versus FAC in adjuvant treatment of node positive breast cancer. *Current Oncology*; 17 (1): 7-16, 2010.

### **Neuman MG**

Seth D, D'Souza El-Guindy N.B., Apte M, Montserrat M, Dooley S, **Neuman M.G**, Haber P, Kundu GC; Darwanto A, de Villiers W, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, A Moles, Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC; Meyer B, Meindl-Beinker NM. Alcohol, Signaling and ECM turnover Alcoholism: Clinical and Experimental Research, 34(1):4-18. 2010.

Shuper P, **Neuman MG**, Kanteres F, Baliunas D, Rehm J. Causal considerations on alcohol and HIV/AIDS a systematic review. *Alcohol and Alcoholism*, 45(2):159-66, 2010.

Nanau R.M., **Neuman MG**. Hypersensitivity syndrome reactions to Ibuprofen. *Translational Research*, 155, 6,2275-293, 2010.

Wong SHY, Happy C, Blinka D, Gock S, Jentzen JM, Donald Hon. J, Coleman H, Jortani SA, Lucire Y, Morris-Kukoski CL, **Neuman MG**, Orsulak PJ, Sander T, Wagner MA, Wynn JR, Wu AHB, Yeo KTJ. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System. *The Pharmacogenomics*, 11, 6, 731-737, 2010.

**Neuman MG**, Oruña L, Coto G, Lago G, Nanau RM, Vincent M. Hyaluronic acid signals for repair in ethanol-induced apoptosis in cultured skin cells *Clin Biochem*, 10.1016, 2010.

### **Nobrega JN**

Hamani, C., Diwan, M., Raymond, R., Fletcher, P., Lozano, A. and **Nobrega, J.N**. Antidepressant-like effects of deep brain stimulation of the medial prefrontal cortex in rats. *Biological Psychiatry*, 67, 117-124. 2010.



Leggio, G.M., Micale, V., Le Foll, B., Mazzola, C., **Nobrega, J.N.** and Drago, F. Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam. *European Neuropsychopharmacology*, 2010 Jun 3. [Epub ahead of print]

Burton, C.L., **Nobrega, J.N.** and Fletcher, P.J. Adolescent methylphenidate self-administration produces sensitization to the locomotor stimulating and neuronal activating effects of amphetamine in adulthood. *Psychopharmacology*, 208, 455-468, 2010.

Hamani, C., Diwan, M., Isabella, S., Lozano, A.M. and **Nobrega, J.N.** Antidepressant-like response of medial prefrontal cortex deep brain stimulation in rats: Effects of different stimulation parameters. *Journal of Psychiatric Research*, 44, 683-687, 2010.

Sander, S.E., **Nobrega, J.N.**, Raymond, R. and Richter, A. Autoradiographic and pharmacological studies on the role of dopamine D3 receptors in genetically dystonic (*dt<sup>SZ</sup>*) hamsters. *Pharmacology Biochemistry and Behavior*, 96, 136-140, 2010.

Creed, M., Hamani, M. and **Nobrega, J.N.** Deep brain stimulation attenuates vacuous chewing movements induced by chronic haloperidol in a rodent model of tardive dyskinesia. *European Neuropsychopharmacology*, 2010 Jul 10. [Epub ahead of print]

Dubiela, F.P., Oliveira, M.G.M., Moreira, K.D., **Nobrega, J.N.**, Tufik, S. and Hipólido, D.C. Inverse benzodiazepine agonist beta-CCM does not reverse learning deficit induced by sleep deprivation. *Neuroscience Letters*, 469, 169-173, 2010.

McCormick, P.N., Kapur, S., Graff-Guerrero, A., Raymond, R., **Nobrega, J.N.** and Wilson, A.A. The antipsychotics olanzapine, risperidone, clozapine and haloperidol are D2-selective *ex vivo* but not *in vitro*. *Neuropsychopharmacology*, 35, 1826-1835, 2010.

Hamani, C. and **Nobrega, J.N.** Deep brain stimulation in an animal model of depression. *European Journal of Neuroscience*, 32, 1109-1117, 2010.

Hamani, C., Lozano, A. and **Nobrega, J.N.** Deep Brain Stimulation in clinical practice and animal models. *Clinical Pharmacology and Therapeutics*, 88, 559-562, 2010.

Natesan, S., Reckless, G.E., Barlow, K.B.L, **Nobrega, J.N.** and Kapur, S. Partial agonists in schizophrenia – why some work and others don't: lessons for future drug development. *International Journal of Neuropsychopharmacology*, 19:1-14, 2010.

Pei, L., Li, S., Wang, M., Diwan, M., Fletcher, P.J., **Nobrega, J.N.** and Liu, F. Uncoupling dopamine D1-D2 receptor complex exerts antidepressant-like effects. *Nature Medicine*, 16, 1393-1395, 2010.

Kessas, M., Creed, M. and **Nobrega, J.N.** An examination of synaptic proteins following chronic haloperidol in a rat model of tardive dyskinesia. *Psychology & Neuroscience*, 3, 229-237, 2010.

## **O'Brien PJ**

Wright J; Hoorman J; Durst T; Asim, M; El-Salfiti, M; Choueiri C; Pratt, MA; Ruddy S; Lau, R; Carlson K; Katzenellenbogen J; **O'Brien PJ**; Wan L; Anderson J "A-CD Estrogens: 1. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds" *Journal of Medicinal Chemistry* (in press), 2010.

Dong Q, Yang K, Wong SM and **O'Brien PJ**. Hepatocyte or serum albumin protein carbonylation by oxidized fructose metabolites: glyceraldehyde or glycolaldehyde as endogenous toxins *Chemico-Biol. Interactions* 188, 31-37, 2010.

Dong, Q, Banaich, MS, **O'Brien PJ**. Cytoprotection by almond skin extracts or catechins of hepatocyte cytotoxicity induced by hydroperoxide (oxidative stress model) versus glyoxal or methylglyoxal (carbonylation model). *Chemico-Biol. Interactions* 185, 101-109, 2010.

Lee O and **O'Brien PJ**. "Modifications of Mitochondrial Function by Toxicants" in Charlene A. McQueen, "Comprehensive Toxicology", Volume 1, pp 411-446 Oxford: Academic Press. Elsevier Publisher, 2010.

Liu Q, Shuhendler A, Cheng J, Rauth AM, **O'Brien PJ**, Wu XY. Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells. *Breast Cancer Research and Treatment* 121 (2) 323-331, 2010.

Chan K, Lemler H, Sivagnanam M, Feng C, Robertson L and **O'Brien PJ**. Cytotoxic effects of polychlorinated biphenyl hydroquinone metabolites in rat hepatocytes. *Journal of Applied Toxicology* 30 (2) 163-171, 2010.

## **O'Dowd BF**

Kabli N, Martin N, Fan T, Nguyen T, Hasbi A, Balboni G, **O'Dowd BF**, George SR. Agonists at the  $\delta$ -opioid receptor modify the binding of  $\mu$ -receptor agonists to the  $\mu$ - $\delta$  receptor hetero-oligomer. *Br J Pharmacol*; 161(5):1122-36, 2010.

Perreault ML, Hasbi A, Alijanian M, Fan T, Varghese G, Fletcher PJ, Seeman P, **O'Dowd BF**, George SR. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. *J Biol Chem.*; 19;285(47):36625-34, 2010.

Verma V, Hasbi A, **O'Dowd BF**, George SR. Dopamine D1-D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: dual functional regulation by G protein-coupled receptor kinase 2. *J Biol Chem.* 5;285(45):35092-103, 2010.

Lee DK, Ferguson SS, George SR, **O'Dowd BF**. The fate of the internalized apelin receptor is determined by different isoforms of apelin mediating differential interaction with beta-arrestin. *Biochem Biophys Res Commun.* 30;395(2):185-9, 2010.

Hasbi A, **O'Dowd BF**, George SR. Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. *Curr Opin Pharmacol.*; 10(1):93-9, 2010.

Ng J, Rashid AJ, So CH, **O'Dowd BF**, George SR. Activation of calcium/calmodulin-dependent protein kinase IIalpha in the striatum by the heteromeric D1-D2 dopamine receptor complex. *Neuroscience.* 20;165(2):535-41, 2010.

El-Ghundi MB, Fan T, Karasinska JM, Yeung J, Zhou M, **O'Dowd BF**, George SR. Restoration of amphetamine-induced locomotor sensitization in dopamine D1 receptor-deficient mice. *Psychopharmacology (Berl.)*; 207(4):599-618, 2010.

### **Ogilvie RI**

Hackam DG, Khan NA Hemmelgarn B, et al including **Ogilvie RI**. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. *Can J Cardiol*; 26: 249-258, 2010.

### **Okey AB**

Moffat ID, Boutros PC, Chen H, **Okey AB** and Pohjanvirta R. Aryl hydrocarbon receptor (AHR)-regulated transcriptomic changes in rats sensitive or resistant to major dioxin toxicities. *BMC Genomics* 11:263 doi:10.1186/1471-2164-11-263, 2010.

Celius T, Pansoy A, Matthews J, **Okey AB**, Henderson MC, Krueger SK & Williams DE. Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver. *Toxicology & Applied Pharmacology* 247:60-69, 2010.

### **Pang KS**

Sun H, **Pang KS**, Response to Letter to the Editor on “Permeability, transport, and metabolism of solutes in the Caco-2 cell monolayer: A theoretical study”. *Drug Metab. Dispos*; 38(5):536-537, 2010.

Chow ECY, Sun H, Khan AA, Groothuis GMM., **Pang KS**, Effects of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and the vitamin D receptor on intestinal and renal transporters, enzymes, and nuclear receptors of the rat. *Biopharm. Drug Dispos*; 31(1):91-108, 2010.

Sun H, Zeng YY, **Pang KS**. Interplay of phase II enzymes and transporters in futile cycling: influence of multidrug resistance-associated protein 2-mediated excretion of estradiol 17beta-D-glucuronide and its 3-sulfate metabolite on net sulfation in perfused TR(-) and Wistar rat liver preparations. *Drug Metab. Dispos*; 38(5):769-780, 2010.

Sun H, **Pang KS**, Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. *Pharm. Res.* 27(7):1237-1254, 2010.

Fan J, Maeng H-J, **Pang KS**, Interplay of transporters and enzymes in the Caco-2 cell monolayer. I. Effect of altered apical secretion. *Biopharm. Drug Dispos*; 31(4):215-227, 2010.

**Pang KS**, Durk M, Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. *J. Pharmacokin. Pharmacodyn*; 37(6): 591-615, 2010.

Fan, J, Chen S, Chow ECY., **Pang KS**, PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. *Curr. Drug Metab*; 11(9):743-761, 2010.

**Pang KS**, Sun H, Chow ECY, Impact of physiological determinants: flow, binding, transporters and enzymes on organ and total body clearances, In *Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges* (KS. Pang, RM Peter, AD Rodrigues, eds) Chapter 5, Springer, New York, pp. 107-147, 2010.

**Pang KS**, Peter RM, Rodrigues AD, Drug-drug interactions: What have we learnt and where are we going? , In, *Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges* (KS. Pang, RM Peter, AD Rodrigues, eds) Chapter 28, Springer, New York, pp. 701-722, 2010.

### **Pace-Asciak CR**

Pouteau E, Aprikian O, Grenot C, Reynaud D, **Pace-Asciak C**, Cuilleron CY, Castañeda-Gutiérrez E, Moulin J, Pescia G, Beysen C, Turner S, Macé K. A low alpha-linolenic intake during early life increases adiposity in the adult guinea pig. *Nutr Metab (Lond)*. 29;7:8, 2010.

### **Park H-W**

Tong Y, Tempel W, Wang H, Yamada H, Shen L, Senisterra GA, MacKenzie F, Chishti AH and **Park HW**. Phosphorylation-independent dual-site binding of the FHA domain of KIF13 Kinesin-3 family members mediates phosphoinositide transport via centaurin alpha1. *PNAS* 107:20346-20351, 2010.

Jiang J, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, **Park HW**, Inglese J, Cantley LC, Auld DS, Thomas CJ. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. *Bioorg Med Chem Lett* 20:3387-3393, 2010.

Wiens CJ, Tong Y, Esmail MA, Gerdes JM, Wang J, Tempel W, Rattner JB, Katsanis N, **Park HW**, Leroux MR. The small GTPase ARL6 (BBS3) localises at or near the ciliary gate and modulates Wnt signaling. *JBC* 285:16218-16230, 2010.

Strushkevich N, Usanov SA, **Park HW**. Structural Basis of Human CYP51 inhibition by antifungal azoles. *JMB* 397:1067-1078, 2010.

Hong BS, Allali-Hassani A, Tempel W, Finerty PJ, Mackenzie F, Vedadi M, **Park HW**. Crystal Structures of Human Choline Kinase Isoforms in Complex with Hemicholinium-3: Single Amino Acid Neighboring Active Site Influences Inhibitor Sensitivity. *JBC* 285:16330-40, 2010.

Boxer MB, Jiang JK, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, **Park HW**, Inglese J, Cantley LC, Thomas CJ. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. *J Med Chem* 53:1048-1055, 2010.

Lepesheva GI, **Park HW**, Hargrove TY, Vanhollebeke B, Wawrzak Z, Harp JM, Sundaramoorthy M, Nes WD, Pays E, Chaudhuri M, Villalta F, Waterman MR. Crystal structure of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. *JBC* 285:1773-1780, 2010.

### **Parker JD**

Gori T, Grotti S, Dragoni S, Lisi M, Sonnati S, Di Stolfo G, Fineschi M, Di Stolfo G, **Parker JD**. Vascular Function Assessment: Flow-mediated constriction complements the information of flow-mediated dilation. *Heart*; 96:141-7, 2010.

Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Thomas GR, Oelze M, Daiber A, **Parker JD**. Tolerance to nitroglycerin-induced preconditioning of the endothelium: A human in-vivo study. *Am J Physiol Heart Circ Physiol*; 298(2):H340-5, 2010.

Liuni A, Luna M, Uxa A, Gori T, **Parker JD**. Rosuvastatin prevents endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2 dependent mechanism. *J Am Coll Card*; 55:1002-6, 2010.

Mariani JA, McDonald MA, Nanthakumar K, **Parker JD**, Ross HJ. Cardiac resynchronization therapy after atrioventricular node ablation for rapid atrial fibrillation in a heart transplant recipient with late allograft dysfunction. *J Heart Lung Transplant*; 29:704-6, 2010.

DiFabio JM, Thomas GR, **Parker JD**. The impact of low dose folic acid on nitroglycerin induced endothelial dysfunction. *Can J Cardiol*. 26:461-5, 2010.

Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, **Parker JD**, Sermer M, Colman JM, Silversides CK. B-type natriuretic peptide in pregnant women with heart disease. *J Am Coll Cardiol*; 56:1247-53, 2010.

Liuni A, Luca MC, Melling M, Lisi M, Dragoni S, Di Stolfo G, Gori T, **Parker JD**. Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function *Am J Physiol Heart Circ Physiol*; 299:H939-45, 2010.

Luca MC, Liuni A, DiFabio J, Gori T, **Parker JD**. Neither captopril nor amiloride prevent endothelial dysfunction induced by ischemia and reperfusion in the human forearm vasculature. *Can J Physiol Pharmacol*; 88:996-1001, 2010.

Liuni A, Luca MC, Di Stolfo G, Uxa A, Mariani J, Gori T, **Parker JD**. Atorvastatin coadministration prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in humans in vivo. *J Am Coll Card*; 57:93-8 19, 2010.

Uxa A, Thomas GR, Gori T, **Parker JD**. Standard Versus Low Dose Transdermal Nitroglycerin: Differential Effects on the Development of Tolerance and Abnormalities of Endothelial Function. *J Cardiovasc Pharmacol.*; 56:354-9, 2010.

Perampaladas K, **Parker JD**, Gori T. The impact of rosiglitazone on nitric oxide bioavailability and endothelial function. *Hemorheol Microcirc.* 2010; 45:325-8

Liuni A, Luca MC, Gori T, **Parker JD**. The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury. *Clin Hemorheol Microcirc.*; 45:161-7, 2010.

Miner SES, Al-Hesayen A, Nield LE, Gori T, **Parker JD**. Acetylcholine acutely induces NOS dysfunction in the human coronary circulation. *Exp Physiol*; 95:1167-76, 2010.

### **Petronis A**

Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. *Nature*.10; 465(7299):721-7, 2010.

Ptak C, Petronis A. Epigenetic approaches to psychiatric disorders. *Dialogues.Clin Neurosci.*; 12(1):25-35. Review, 2010.

### **Piquette-Miller M**

Petrovic V, **Piquette-Miller M**. Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats. *Drug Metab Dispos.* 38(10):1760-6, 2010.

Vassileva V, **Piquette-Miller M**. Inflammation: extinguishing the fires within. *Clin Pharmacol Ther.* 87(4):375-9, 2010.

De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, **Piquette-Miller M**. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. *Mol Cancer Ther.* 9(6):1820-30, 2010.

Pollex EK, Anger G, Hutson J, Koren G, **Piquette-Miller M**. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. *Drug Metab Dispos.* 38(5):740-4, 2010.

Anger GJ, **Piquette-Miller M**. Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes. *J Pharmacol Exp Ther.* 334(1):21-32, 2010.

De Souza R, Zahedi P, Allen CJ, **Piquette-Miller M**. Polymeric drug delivery systems for localized cancer chemotherapy. *Drug Deliv.* 17(6):365-75, 2010.

Gahir SS, **Piquette-Miller M**. Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice. *Drug Metab Dispos.*;39(3):465-71, 2010.

Zahedi P, De Souza R, Huynh L, **Piquette-Miller M**, Allen C. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. *Mol Pharm.* 7; 8(1):260-9. 2010.

### **Salahpour A**

Sotnikova TD, Beaulieu JM, Espinoza S, Masri B, Zhang X, **Salahpour A**, Barak LS, Caron MG, Gainetdinov RR. The dopamine metabolite 3-methoxytyramine is a neuromodulator. *PLoS One.* 18; 5(10):e13452, 2010.

Dzirasa K, Phillips HW, Sotnikova TD, **Salahpour A**, Kumar S, Gainetdinov RR, Caron MG, Nicolelis MA. Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony. *J Neurosci.* 5; 30(18):6387-97, 2010.

### **Schapira M**

Wang M, Mok MW, Harper H, Lee WH, Min J, Knapp S, Oppermann U, Marsden B, **Schapira M**. Structural Genomics of Histone Tail Recognition; *Bioinformatics.* 15; 26(20):2629-30, 2010.

Campagna-Slater V, **Schapira M**. -Finding inspiration in the Protein Data Bank to chemically antagonize readers of the histone code. *Molecular Informatics.* 29:322-331, 2010.

Zhao R, Leung E, **Schapira M**, Houry WA. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. *PLoS One* 1:5(4):e9934, 2010.

Campagna-Slater V, Arrowsmith AG, Zhao Y, **Schapira M**. Pharmacophore screening of the Protein Data Bank for specific binding site chemistry. *J Chem Inf Model.* 50(3)358-67, 2010.

Wu H, Min J, Lunin VL, Antoshenko T, Dombrovski L, Zeng H, Allali-Hassani A, Campagna-Slater V, Vedadi M, Arrowsmith CH, Plotnikov AN, **Schapira M**. Structural biology of human H3K9 Methyltransferases. *PLoS One*; 11;5(1):e8570, 2010.

### **Schimmer BP**

**Schimmer BP**, White PC. Mini review: steroidogenic factor 1: its roles in differentiation, development, and disease. *Mol Endocrinol*; 24(7): 1322-37, 2010.

### **Seeman P**

**Seeman P**. Historical Introduction to The Dopamine Receptors. In: *The Dopamine Receptors*, 2nd edition, edited by K.A. Neve, Humana Press, New York, pp. 1-21, 2010.

Novak, G., and **Seeman P**. Hyperactive mice show elevated D2High receptors, a model for schizophrenia: calcium/calmodulin-dependent kinase II alpha knockouts. *Synapse* 64(10): 794-800, 2010.

Lipina, T.V., Niwa M, Jaaro-Peled H, Fletcher PJ, **Seeman P**, Sawa A and Roder JC. Enhanced dopamine function in mutant DISC1-L100P mutant: Implications for schizophrenia. *Genes, Brain & Behaviour* 9(7): 777-789, 2010.

Perreault JL, Hasbi A, Aliganiaram M, Fan T, Varghese G, Fletcher PJ, **Seeman P**, O'Dowd BF, George SR. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. *J. Biol. Chem.* 285: 36625-36634, 2010.

Wang M, Pei L, Fletcher PJ, Kapur S, **Seeman P.**, Liu F. Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: Increased dopamine D2 receptor dimerization. *Mol. Brain* 3(1): 25-34, 2010.

Fligel SB, Robinson TE, Clark JJ, Clinton SM, Watson SJ, **Seeman P**, Phillips PEM, Akil H. An animal model of genetic vulnerability to behavioral disinhibition and responsiveness to reward-related cues: Implications for addiction. *Neuropsychopharmacology* 35: 388-400, 2010.

**Seeman P.** Dopamine D2 Receptors as Treatment Targets in Schizophrenia. *Translational Medicine Review. Clin. Schizophrenia & Related Psychoses* April: 56-73, 2010.

Franco R, **Seeman P**, Barrera C, Aymerich M. Cocaine self-administration markedly increases dopamine D2 receptor negative cooperativity for dopamine binding: A receptor dimer-based analysis. *Synapse* 64: 566-569, 2010.

Novak F, **Seeman P**, Le Foll B. Exposure to nicotine produces an increase in dopamine D2High receptors: a possible mechanism for dopamine hypersensitivity. *Int. J. Neurosci.* 691-697, 2010.

Remington G, **Seeman P**, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebo-controlled trial. *J. Clin. Psychiat.* 71: 1-7. Epub Sept. 7, 2010.

### **Sellers EM**

Schoedel KA, McMorn S, Chakraborty B, Zerbe K, **Sellers EM.** Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. *Pain Physician.*;13(6):561-73, 2010.

Mansbach RS, Schoedel KA, Kittrelle JP, **Sellers EM.** The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. *Drug Alcohol Depend.* 112(3):173-7, 2010.

Milovan D, Almeida L, Romach MK, Nunes T, Rocha JF, Sokowloska M, **Sellers EM**, Soares-da-Silva P. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. *Epilepsy Behav.* 18(4):366-73, 2010.

Schoedel KA, Meier D, Chakraborty B, Manniche PM, **Sellers EM.** Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. *Clin Pharmacol Ther.*; 88(1):69-78, 2010.



Mwenifumbo JC, Zhou Q, Benowitz NL, **Sellers EM**, Tyndale RF. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. *Pharmacogenomics*. 11(2):189-98, 2010.

Shram MJ, Sathyan G, Khanna S, Tudor IC, Nath R, Thippawong J, **Sellers EM**. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. *J Clin Psychopharmacol*. 30(1):25-33, 2010.

Zawertailo LA, Tyndale RF, Busto U, **Sellers EM**. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. *Hum Psychopharmacol*. 25(1):71-9, 2010.

Shram MJ, **Sellers EM**, Romach MK. Oral ketamine as a positive control in human abuse potential studies. *Drug Alcohol Depend*. 1;114(2-3):185-93, 2010.

### **Semple JW**

**Semple JW**, Freedman J: Platelets and Innate Immunity. *Cell Mol Life Sci*. 67(4):499–511, 2010.

Chow L, Speck ER, Kim M, Aslam R, Webster M, Chen O, Ni H, Sahib K, Garvey MB, Sheridan BL, Freedman J, **Semple JW**. A novel mouse model demonstrating both antibody- and T cell-mediated thrombocytopenia: Differential response to IVIG. *Blood*. 115(6):1247-1253, 2010.

Brinc D, Le-Tien H, Crow AR, **Semple JW**, Freedman J, Lazarus AH: Transfusion of antibody-opsionized red blood cells results in a shift in the immune response from the red blood cell to the antibody in a murine model of ITP. *Transfusion* 50:2016-2025, 2010.

Fung YL, Kim M, Tabuchi A, Aslam R, Speck ER, Chow L, Kuebler W, Freedman J, **Semple JW**: Recipient T lymphocytes modulate the severity of antibody-mediated transfusion-related acute lung injury (TRALI). *Blood* 116(16):3073-3079, 2010.

Chow L, **Semple JW**: Etiology and pathophysiology of ITP: The basic Immunology of ITP. In: *Immune Thrombocytopenia (ITP)*, 1<sup>st</sup> edition, (T Kuhne, ed). Uni-Med Verlag AG, Bremen, International Medical Publishers, London/Boston, pp26-47. 2010.

Provan A, Newland AD, **Semple JW**: Autoimmune haematological disorders (Chapter 23). In: *Molecular Haematology*, 3th edition, (A. Provan, JG Gribben, eds). Wiley-Blackwell, London, UK, pp 287-305. 2010.

**Semple JW**. Animal models of immune thrombocytopenia (ITP). *Ann Haematol* 89 (Suppl 1):S37–S44, 2010.

Zehnder JL, **Semple JW**, Imbach P, Neufeld EJ, Buchanan GR, Cines DB. Future Research in ITP: An ICIS consensus. *Ann Haematol* 89 (Suppl 1): S19-S23, 2010.

**Semple JW**, Provan D, Garvey MB, Freedman J. Recent progress in understanding the pathogenesis of immune thrombocytopenia (ITP). *Curr Opin Haematol* 17:590-595, 2010.

**Semple JW:** Anti-D: Basic Concepts and Mechanisms of Action in Autoimmunity; Chapter 9. In: Immunoglobulin Therapy (AH Lazarus and JW Semple, eds). AABB Press, Bethesda, MD, pp.159-173. 2010.

### **Shear NH**

Winnicki M, **Shear NH.** A systematic approach to systemic contact dermatitis and SDRIFE: A closer look at these conditions and an approach to intertriginous eruptions. *Am J Clin Dermatol* 2010. In press.

Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M. Global Alliance to Improve Outcomes in Acne (incl. **NH Shear**). Large-scale worldwide observational study of adherence with acne therapy. *Int J Dermatol* 49(4): 448-56, 2010.

### **Snead OC**

Kwan A, Ng WH, Otsubo H, Ochi A, **Snead OC 3rd**, Tamber MS, Rutka JT. Hemispherectomy for the control of intractable epilepsy in childhood: comparison of 2 surgical techniques in a single institution. *Neurosurgery*. 2010 Dec;67(2 Suppl Operative):429-36, 2010.

Akiyama T, Chan DW, Go CY, Ochi A, Elliott IM, Donner EJ, Weiss SK, **Snead OC 3rd**, Rutka JT, Drake JM, Otsubo H. Topographic movie of intracranial ictal high-frequency oscillations with seizure semiology: epileptic network in Jacksonian seizures. *Epilepsia*. 2;52(1):75-83, 2010.

Widjaja E, Yeung R, Geibprasert S, Mahmoodabadi SZ, **Snead OC 3rd**, Smith ML. Longitudinal brain volumes in children with intractable partial seizures. *Pediatr Neurol*.; 42(5):315-9, 2010.

Dracopoulos A, Widjaja E, Raybaud C, Westall CA, **Snead OC 3rd**. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. *Epilepsia*.; 51(7):1297-304, 2010.

Simao G, Raybaud C, Chuang S, Go C, **Snead OC 3rd**, Widjaja E. Diffusion tensor imaging of commissural and projection white matter in tuberous sclerosis complex and correlation with tuber load. *AJNR Am J Neuroradiol*.; 31(7):1273-7, 2010.

Widjaja E, Simao G, Mahmoodabadi SZ, Ochi A, **Snead OC 3rd**, Rutka J, Otsubo H. Diffusion tensor imaging identifies changes in normal-appearing white matter within the epileptogenic zone in tuberous sclerosis complex. *Epilepsy Res*. 89(2-3):246-53, 2010.

Cortez MA, Li C, Whitehead SN, Dhani SU, D'Antonio C, Huan LJ, Bennett SA, **Snead OC 3rd**, Bear CE. Disruption of CIC-2 expression is associated with progressive neurodegeneration in aging mice. *Neuroscience*. 28;167(1):154-62, 2010.

Bhardwaj RD, Mahmoodabadi SZ, Otsubo H, **Snead OC 3rd**, Rutka JT, Widjaja E. Diffusion tensor tractography detection of functional pathway for the spread of epileptiform activity between temporal lobe and Rolandic region. *Childs Nerv. Syst.*; 26(2):185-90, 2010.

### **Toal, C**

Anschutz, M, Wonnemann M, Schug B, **Toal C**, Donath F, Pontius A, Pauli K, Brendel E, Blume H. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. *Int J Clin Pharmacol Ther*; 48(2):158-170, 2010.

Brendel E, Pauli K, Pontius A, **Toal C**. Letter to the Editor. *Int J Clin Pharmacol Ther*; 48(6):416-418, 2010.

### **Tyndale RF**

Zawertailo L, **Tyndale RF**, Busto UE, Sellers EM. Effect of metabolic blockade on the psychoactive properties of dextromethorphan. *Human Psychopharmacology, Clinical and Experimental*, 25: 71–79, 2010.

Grieder T, Sellings LH, Vargas-Perez H, Sui E, Ting-A-Kee R, **Tyndale RF** and van der Kooy D. Dopaminergic signaling mediates nicotine dependent withdrawal aversions but not the motivational effects of acute nicotine withdrawal. *Neuropsychopharmacology*, 35(4): 943-54, 2010.

Al Koulsi N, Hoffmann EB, Assadzadeh A, and **Tyndale RF**. Hepatic CYP2A6 levels and nicotine metabolism: Impact of genetic, physiologic, environmental, and epigenetic factors. *European Journal of Clinical Pharmacology*, 66(3): 239-51, 2010.

Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, **Tyndale RF**. New *CYP2A6* gene deletion and conversion variants in a population of Black African descent *Pharmacogenomics*, 11(2): 189-98, 2010.

Mann A, **Tyndale RF**. CYP2D6 enzyme neuroprotects against MPP<sup>+</sup> toxicity in SH-SY5Y neuronal cells. *European Journal of Neuroscience*, 31(7): 1185-93, 2010.

Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, **Tyndale RF**. Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended Duration Transdermal Nicotine Therapy. *Clin Pharmacol Ther*, 87(5): 553-7, 2010.

Al Koulsi N and **Tyndale RF**. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. *Xenobiotica*, 40(6): 381-92, 2010.

Khokhar JY, **Tyndale RF**. Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. *Brain Research*, 1348: 1-9, 2010.

Al Koudsi N, O'Loughlin J, Rodriguez D, Audrain-McGovern J, **Tyndale RF**. Investigating apparently discordant findings on CYP2A6 and the risk of nicotine dependence in adolescent smokers. *Journal of Pediatric Biochemistry*, 1: 105-123, 2010.

Khokhar JY, Ferguson CS, Zhu AZX, **Tyndale RF**. Pharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment. *Annual Reviews of Pharmacology and Toxicology*, 50: 39–61, 2010.

Miksysis SL and **Tyndale RF**. Neurodegenerative diseases: A growing challenge. Editorial. *Clinical Pharmacology and Therapeutics*, 88(4):427-30, 2010.

Ho MK, Goldman D, Heinz A, Kaprio J, Kreek MJ, Li MD, Munafò MR, **Tyndale RF**. Breaking barriers in the genomics and pharmacogenetics of drug addiction. *Clinical Pharmacology and Therapeutics*, 88(6): 779-91, 2010.

Mroziewicz M and **Tyndale RF**. Applying Pharmacogenetics to Drug Dependence and Treatment. *Addiction Science & Clinical Practice*, NIDA press, 5(2): 17-29, 2010.

### **Utrecht JP**

Li J, Zhu X, Liu F, Cai P, Sanders C, Lee W, **Utrecht J**: Cytokine and autoantibody patterns in acute liver failure. *J. Immunotox.* 7(3): 157-164, 2010.

Adams DH, Ju C, Ramaiah SK, **Utrecht J**, Jaeschke H: Mechanisms of immune-mediated liver injury. *Toxicol. Sci.* 115(2): 307-321, 2010.

Iverson S, Kautiainen A, Ip J, **Utrecht JP**: Effect of clozapine on neutrophil kinetics in rabbits. *Chem. Res. Toxicol.* 23: 1184-1191, 2010.

Li J, **Utrecht JP**. The danger hypothesis applied to idiosyncratic drug reactions. *Handb Exp Pharmacol*; (96): 493-509, 2010.

Popovic M, Shenton JM, Chen J, Baban A, tharmanathan T, Mannargudi B, Abdulla D, **Utrecht JP**. Nevirapine hypersensitivity. *Handb Exp Pharmacol*; (196): 437-51, 2010.

### **Warsh JJ**

**Kish SJ**, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[<sup>11</sup>C]DASB and structural brain imaging study. *Brain*. 133 (Pt 6):1779-97, 2010.

Perova T, Kwan M, Li PP, **Warsh JJ**. Differential modulation of intracellular Ca<sup>2+</sup> responses in B lymphoblasts by mood stabilizers. *Int J europsychopharmacol*;13(6):693-702, 2010.

## **Wells JW**

Pisterzi LF, Jansma DB, Georgiou J, Woodside MJ, Chou JT, Angers S, Raicu V, Wells JW. Oligomeric size of the M<sub>2</sub> muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer. *J Biol Chem.* 28;285(22):16723-38, 2010.

## **Wells PG**

Jeng W and **Wells PG**. Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice. *ACS Chem. Neurosci.* 1(5): 366-380, 2010.

Sweeting JN, Siu M, McCallum GP, Miller L and **Wells PG**. Species differences in methanol and formic acid pharmacokinetics in mice, rabbits and primates. *Toxicol. Appl. Pharmacol.* 247(1): 28-35, 2010.

**Wells PG**, McCallum GP, Lam KCH, Henderson JT and Ondovcik SL. Oxidative DNA damage and repair in teratogenesis and neurodevelopmental deficits. *Birth Defects Research Part C: Embryo Today: Reviews* 90(2): 103-109, 2010.

**Wells PG** and Winn LM. Chapter 12.08. The role of biotransformation in developmental toxicity. In: *Comprehensive Toxicology*, 2<sup>nd</sup> edition, CA McQueen (ed.), vol. 12, Developmental Toxicology, GP Daston and TB Knudsen (eds.), pp.95-115, Elsevier Ltd., Oxford, 2010.

## **Wong ACH**

Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL, **Wong AH**: Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. *International Clinical Psychopharmacology*; 25(5):264-9, 2010.

Souza RP, De Luca V, Remington G, Lieberman J, Meltzer H, Kennedy JL, **Wong AH**: Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. *Psychopharmacology (Berl)*; 210(3):347-54, 2010.

Sarras H, Semeralul MO, Fadel MP, Feldcamp LA, Labrie V, **Wong AH**: Elevated PICK1 mRNA in schizophrenia and increased SRR mRNA in suicide. *Schizophrenia Research*; 120(1-3):236-7, 2010.

Souza RP, Romano-Silva M, Lieberman JA, Meltzer HY, MacNeil LT, Culotti JG, Kennedy JL, **Wong AH**: Genetic association of the GDNF alpha receptor genes with schizophrenia and clozapine response, *Journal of Psychiatric Research*; 44(11):700-6, 2010.

## **Young T**

Andreazza AC, Shao L, Wang JF, **Young LT**. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. *Arch Gen Psychiatry.* 67(4):360-8, 2010.

Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, Chillotti C, Cichon S, Czerski P, Del Zompo M, DeteraWadleigh SD, Grof P, Gruber O, Hashimoto R, Hauser J, Hoban R, Iwata N, Kassem L, Kato T, Kittel-Schneider S, Kliwicki S, Kelsoe JR, Kusumi I, Laje G, Leckband SG, Manchia M, Macqueen G, Masui T, Ozaki N, Perlis RH, Pfennig A, Piccardi P, Richardson S, Rouleau G, Reif A, L. Young T 25 Rybakowski JK, Sasse J, Schumacher J, Severino G, Smoller JW, Squassina A, Turecki G, **Young LT**, Yoshikawa T, Bauer M, McMahon FJ. The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. *Neuropsychobiology*. 8;62(1):72-78, 2010.

de Lara CL, Jaitovich Groisman I, Lebel V, Mamdani F, Cruceanu C, Yerko V, Beck A, **Young LT**, Rouleau G, Grof P, Alda M, Turecki G. Implication of synapse related genes in bipolar disorder by linkage and gene expression analyses. *International Journal of Neuropsychopharmacology*, 13(10):1397-410, 2010.

Che Y, Wang JF, Shao L, **Young LT**. Damage to RNA but not DNA in the hippocampus of patients with major mental illness. *J Psychiatry Neurosci.*; 35(5):296-302, 2010.

Segal ZV, Levitan R, **Young LT**, Cooke R, Bieling P, Bloch R; Martin L, MacQueen G. Antidepressant Monotherapy versus Sequential Pharmacotherapy and Mindfulness-Based Cognitive Therapy, or Placebo, for Relapse Prophylaxis in Recurrent Depression. *Arch Gen Psychiatry*; 67(12):1256-64, 2010.

Gigante AD, **Young LT**, Yatham LN, Andreazza AC, Nery FG, Grinberg LT, Heinsen H, Lafer B. Morphometric post-mortem studies in bipolar disorder: possible association and oxidative stress and apoptosis. *Int J Neuropsychopharmacol*. 23:1-15, 2010.

### **Zack M**

**Zack M.**, Woodford, TM, Tremblay AM, Steinberg L., Zawertailo LA, Busto UE. Stress and alcohol cues exert conjoint effects on go and stop signal responding in male problem drinkers. *Neuropsychopharmacology*, 36 (2): 445-58, 2010.

Tremblay AM, Desmond RC, Poulos CX, & **Zack M**. Haloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. *Addiction Biology*, 16 (3): 467-84, 2010.

Hussain S, Zawertailo L, Busto U, **Zack M**, Farvolden P, & Selby P. The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: a randomized controlled trial in unmotivated smokers. *Addictive Behaviors*, 35, (2): 164-167, 2010.

### **Zawertailo L**

Hussain S, Zawertailo L, Busto U, Zack M, Selby P. The impact of chronic bupropion on plasma cotinine and on the subjective effects of *ad lib* smoking: a randomized controlled trial in unmotivated smokers. *Addictive Behaviour*; 35(2):164-167, 2010.

Yasseen B, Kennedy, JL, **Zawertailo L**, Busto U. Comorbidity between bipolar disorder and alcohol use disorder: A genetic analysis. *Psychiatry Research*; 176(1):30-33, 2010.

**Zawertailo LA**, Busto UE, Tyndale RF, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. *Hum Psychopharmacol*; 25(1):71-79, 2010.

Busto A, Souza RP, Lobo DS, Shaikh SA, **Zawertailo LA**, Busto UE, Kennedy JL. Cocaine and amphetamine regulated transcript (CART) gene in the comorbidity of schizophrenia with alcohol use disorders and nicotine dependence. *Prog. Neuropsychopharmacol Biol Psychiatry*; 34(6):834-836, 2010.

Kushnir V, Menon M, Balducci X, Selby PL, Busto U, **Zawertailo L**. Enhanced smoking cue salience associated with depression severity in nicotine-dependent individuals: An fMRI study. *Int J Neuropsychopharmacology* 7:1-12, 2010.

Selby P, Voci S, **Zawertailo L**, George TP, Brands B. Individualized Smoking Cessation Treatment in an Outpatient Setting: Predictors of Outcome in a Sample with Psychiatric and Addictions Co-Morbidity. *Addictive Behaviors*; 35(9):811-817, 2010.

Voci S, Bondy S, **Zawertailo L**, Walker L, George TP, Selby PL. Impact of a smoke-free policy in a large psychiatric hospital on staff attitudes and patient behaviour. *Gen Hosp Psychiatry* :32(6):623-630, 2010.

Zack M, Woodford TM, Tremblay AM, Steinberg L, **Zawertailo LA**, Busto UE. Stress and alcohol cues exert conjoint effects on Go and Stop signal responding in male problem drinkers. *Neuropsychopharmacology*: 36(2):445-458, 2010.

Costello MJ, Sproule B, Victor JC, Leatherdale S, **Zawertailo L**, Selby PL. Effectiveness of pharmacist counseling combined with nicotine replacement therapy: a pragmatic randomized trial with 6,987 participants. *Cancer Causes and Control*; 22(2):167-180, 2010.

### **Ph.D. Theses (2010)**

Al Koudsi, Nael (2010) CYP2A6 and CYP2B6: Sources of Variation and their Role in Nicotine Metabolism. Supervisor: Dr. R.F. Tyndale.

Gill, Simerpal (2010) Investigating Sources of Variability in Pharmacological Response to Nausea and Vomiting of Pregnancy. Supervisor: Dr. G. Koren

Ramadeen, Andrew (2010) Investigation of the Effects of n-3 Polyunsaturated Fatty Acids on Vulnerability to Atrial Fibrillation and Cardiomyopathy. Supervisor: Dr. P. Dorian.

### **M.Sc. Theses (2010)**

Cui, Zhe (2010). Developmental Profile of Hepatic CYP2B Expression, In Vivo and In Vitro Nicotine Metabolism in Rats. Supervisor: Dr. R.F. Tyndale.

Emami, Arian. (2010). Strain and Sex Differences in the Hepatotoxicity of 4-Aminobiphenyl in the Mouse. Supervisor: Dr. D.M. Grant.

Lo, Ching-Han (2010). Concurrent Self-Administration of Alcohol and Nicotine in an Operant Paradigm. Supervisor: Dr. A.D. Le.

Moller, Monique (2010). Detection of Prenatal Opiate Exposures in Alternative Matrices. Supervisor: Dr. G. Koren.

Pasiliao, Clarissa (2010). The Role of Glutathione in the Neuroprotective Effect of Mood Stabilizers. Supervisor: Dr. P.P. Li and Dr. J.J. Warsh.

Perampaladas, Kumar (2010). Effects of Rosiglitazone in a Nitroglycerin-Induced Model of Endothelial Dysfunction. Supervisor: Dr. J.D. Parker.

Sacco, Raffaele (2010). Cockayne Syndrome B is Required for Neural Precursor Self-renewal and Neuritegenesis After DNA Damage. Supervisor(s): Dr. R. Laposa and Dr. D.M. Grant.

Staios, Gregory (2010). Effect of Varenicline vs. Placebo on Reactivity to Tobacco and Alcohol Cues in Smokers who are Light Drinkers. Supervisor: Dr. U. Busto.

Tam, Carolyn (2010). Circulating Unmetabolized Folic Acid: Relation to Folate Status and Effect of Supplementation. Supervisor: Dr. G. Koren.

Wong, Amy (2010). Neuropathology of Post-Stroke Depression: Possible Role of Inflammatory Molecules and Indoleamine 2,3 Dioxygenase. Supervisor: Dr. K. Lanctôt.

Zou, Sheng (2010). The Effect of Stress on Nicotine Self-Administration in Adolescent and Adult Rats. Supervisor: Dr. A.D. Le.